Abstract
Introduction
Studies in breast cancer (BC) have been shown that many tumor cells carry mutations
that disrupt the DNA damage response mechanism. In eukaryotic cells, the overexpression
or deprivation of DSBs repair genes is linked closely to a higher risk of cancer.
Patients and Methods
In this study, mRNA expression levels of some genes, such as Tip60, ATM, p53, CHK2,
BRCA1, H2AX, which are associated with DNA damage repair, were measured using RT-PCR
method in tumor and matched-normal tissues of 58 patients with BC.
Results
According to the study results, 55% in Tip60, 59% in ATM, 57% in BRCA1, 48% in H2AX,
66% in CHK2, and 43% in p53 decreased in tumor tissue of patients compared to the
matched normal tissue. When evaluated according to molecular subtypes, expression
of all genes in the pathway was found significantly higher in normal tissues than
in tumor tissues especially in Luminal B and Luminal B+HER2 groups. One of the most
important results of the study is that CHK2 mRNA expressions in normal tissues were
higher than tumor tissue in 90% of patients in Luminal B and Luminal B-HER2 + groups.
This is the first study showing DNA repair genes’ expressions in molecular subtypes
of breast cancer. In general, the decrease in the expression of DNA damage repair
genes in tumor tissue indicates that these genes may have a role in the development
of BC. Our study results also suggest that CHK2 may be a candidate marker in the molecular
classification of breast cancer
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA: A Cancer J Clin. 2021; 71: 209-249https://doi.org/10.3322/caac.21660
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Arch Pathol Lab Med. 2007; 131 ([18:Asocco]2.0.Co;2): 18-43https://doi.org/10.1043/1543-2165(2007)131
- Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.Breast Cancer Res Treat. 2017; 161: 245-258https://doi.org/10.1007/s10549-016-4049-8
- Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer.J Clin Oncol. 1983; 1: 227-241https://doi.org/10.1200/jco.1983.1.4.227
- Molecular portraits of human breast tumours.Nature. 2000; 406: 747-752https://doi.org/10.1038/35021093
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.J Am Med Assoc. 2006; 295: 2492-2502https://doi.org/10.1001/jama.295.21.2492
- Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol. 2011; 22: 1736-1747https://doi.org/10.1093/annonc/mdr304
- Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients.Ann Diagn Pathol. 2014; 18: 21-26https://doi.org/10.1016/j.anndiagpath.2013.10.005
- The differences in CXCR4 protein expression are significant for the five molecular subtypes of breast cancer.Ultrastruct Pathol. 2012; 36: 381-386https://doi.org/10.3109/01913123.2012.728687
- Lifestyle-related factors and environmental agents causing cancer: an overview.Biomedicine & Pharmacotherapy. 2007; 61: 640-658https://doi.org/10.1016/j.biopha.2007.10.006
- DNA damage and breast cancer.World J Clin Oncol. 2011; 2: 329-338https://doi.org/10.5306/wjco.v2.i9.329
- Epigenetic modifications in double-strand break DNA damage signaling and repair.Clin Cancer Res. 2010; 16: 4543-4552https://doi.org/10.1158/1078-0432.CCR-10-0513
- Cellular functions of TIP60.Int J Biochem & Cell Biology. 2006; 38: 1496-1509https://doi.org/10.1016/j.biocel.2006.03.003
- A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM.Proc Natl Acad Sci USA. 2005; 102: 13182-13187https://doi.org/10.1073/pnas.0504211102
- Promoter Hypermethylation of the ATM Gene as a Novel Biomarker for Breast Cancer.Asian Pac J Cancer Prev. 2017; 18: 3003-3009https://doi.org/10.22034/apjcp.2017.18.11.3003
- Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer.Comput Struct Biotechnol J. 2021; 19: 4101-4109https://doi.org/10.1016/j.csbj.2021.07.014
- Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase.Genes & Development. 2010; 24: 333-338https://doi.org/10.1101/gad.1863810
- Tip60 in DNA damage response and growth control: many tricks in one HAT.Trends Cell Biol. 2006; 16: 433-442https://doi.org/10.1016/j.tcb.2006.07.007
- Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair.Nature. 2002; 419: 411-415https://doi.org/10.1038/nature01035
- Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response.Nature. 2007; 448: 1063-1067https://doi.org/10.1038/nature06055
- Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development.Oncogene. 2003; 22: 2466-2477https://doi.org/10.1038/sj.onc.1206342
- Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks.Nat Cell Biol. 2006; 8: 91-99https://doi.org/10.1038/ncb1343
- Down-regulation of Tip60 gene as a potential marker for the malignancy of colorectal cancer.Anticancer Res. 2009; 29: 3953-3955
- Role of Tip60 tumor suppressor in DNA repair pathway.Chin Sci Bull. 2011; 56: 1212-1215https://doi.org/10.1007/s11434-011-4433-z
- Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis.Mol Cell. 2006; 24: 827-839https://doi.org/10.1016/j.molcel.2006.11.021
- Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60.Nat Cell Biol. 2009; 11: 1376-1382https://doi.org/10.1038/ncb1982
- Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.Neoplasia. 2014; 16: 982-991https://doi.org/10.1016/j.neo.2014.09.009
- ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.Br J Cancer. 2015; 112: 1059-1066https://doi.org/10.1038/bjc.2015.60
- ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas.Ann Oncol. 2014; 25: 69-75https://doi.org/10.1093/annonc/mdt421
- ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels.Br J Cancer. 2015; 112: 1059-1066https://doi.org/10.1038/bjc.2015.60
- Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with Taxanes.Anticancer Res. 2006; 26: 695-701
- BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry.J Histochem Cytochem. 2005; 53: 621-629https://doi.org/10.1369/jhc.4A6544.2005
- Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene.Int J Cancer. 1999; 80: 823-826https://doi.org/10.1002/(sici)1097-0215(19990315)80:6<823::aid-ijc5>3.0.co;2-3
- Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors.Cell. 2003; 114: 359-370https://doi.org/10.1016/s0092-8674(03)00566-x
- Poor prognosis of constitutive γ-H2AX expressing triple-negative breast cancers is associated with telomere length.Biomark Med. 2015; 9: 383-390https://doi.org/10.2217/bmm.15.2
- Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer.Radiother Oncol. 2011; 101: 39-45https://doi.org/10.1016/j.radonc.2011.07.009
- H2AX haploinsufficiency modifies genomic stability and tumor susceptibility.Cell. 2003; 114: 371-383https://doi.org/10.1016/s0092-8674(03)00567-1
- Chromatin structure and DNA double-strand break responses in cancer progression and therapy.Oncogene. 2007; 26: 7765-7772https://doi.org/10.1038/sj.onc.1210874
- Control of radiosensitivity of F9 mouse teratocarcinoma cells by regulation of histone H2AX gene expression using a tetracycline turn-off system.Cancer Res. 2004; 64: 4131-4136https://doi.org/10.1158/0008-5472.Can-03-2566
- Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy.J Biol Chem. 2004; 279: 2273-2280https://doi.org/10.1074/jbc.M310030200
- Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.Oncotarget. 2015; 6: 42773-42780https://doi.org/10.18632/oncotarget.6001
- CHK2 kinase in the DNA damage response and beyond.J Mol Cell Biol. 2014; 6: 442-457https://doi.org/10.1093/jmcb/mju045
- The combined status of ATM and p53 link tumor development with therapeutic response.Genes & Development. 2009; 23: 1895-1909https://doi.org/10.1101/gad.1815309
Article info
Publication history
Published online: November 11, 2022
Accepted:
October 24,
2022
Received in revised form:
September 29,
2022
Received:
May 11,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
